CuraSen Therapeutics Inc

CuraSen Therapeutics Inc. is a privately held biopharmaceutical company headquartered in San Carlos, California. With a team of 20 employees, the company is focused on developing innovative treatments for neurodegenerative diseases. CuraSen's primary focus is on advancing novel therapies for neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, as well as several orphan indications. Their approach centers around restoring a crucial pathway originating from the locus coeruleus, an area of the brain that exhibits early signs of pathology in these diseases. The company's development program is supported by a strong foundation of research and clinical testing. They began evaluating their hypothesis in 2019 using existing drugs from other therapeutic areas, which has informed the development of their first new chemical entity, CST-2032. This compound entered clinical trials in September 2020. CuraSen Therapeutics Inc. can be reached through their website at curasen.com.